SG11201806304PA - Dry powder inhaler - Google Patents

Dry powder inhaler

Info

Publication number
SG11201806304PA
SG11201806304PA SG11201806304PA SG11201806304PA SG11201806304PA SG 11201806304P A SG11201806304P A SG 11201806304PA SG 11201806304P A SG11201806304P A SG 11201806304PA SG 11201806304P A SG11201806304P A SG 11201806304PA SG 11201806304P A SG11201806304P A SG 11201806304PA
Authority
SG
Singapore
Prior art keywords
international
dry powder
pct
diseases
powder inhaler
Prior art date
Application number
SG11201806304PA
Inventor
P Spencer Kinsey
Brendan Laurenzi
Chad Smutney
Benoit Adamo
Joseph Guarneri
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of SG11201806304PA publication Critical patent/SG11201806304PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A61M15/0025—Mouthpieces therefor with caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/10—General characteristics of the apparatus with powered movement mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
    • A61M2205/121—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit interface between cassette and base
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
    • A61M2205/128—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit with incorporated valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/14—Static flow deviators in tubes disturbing laminar flow in tubes, e.g. archimedes screws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2207/00—Methods of manufacture, assembly or production

Abstract

WO 17 / 13 260 1 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/132601 Al 3 August 2017 (03.08.2017) WIPO I PCT 111111111111110111011111111111010111110111111110111111111111111111011111111111110111111 (51) International Patent Classification: A61K 9/00 (2006.01) A61M 15/00 (2006.01) (21) International Application Number: PCT/US2017/015486 (22) International Filing Date: 27 January 2017 (27.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/289,095 29 January 2016 (29.01.2016) US (72) Inventors: KINSEY, P. Spencer; 6 Quail Hollow Lane, Sandy Hook, CT 06482 (US). LAURENZI, Brendan; 130 Richardson Dr., Middlebury, CA 06762 (US). SMUT- NEY, Chad, C.; 1501 Bunker Hill Rd., Watertown, CT 06795 (US). ADAMO, Benoit; 255 West Street, Apt. 2G, Mount Kisco, NY 10549 (US). GUARNERI, Joseph; 72 Published: Geriak Rd., Stamford, CT 06905 (US). (74) Agents: CULLMAN, Louis, C. et al.; K&L Gates LLP, 1 Park Plaza, Twelfth Floor, Irvine, CA 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). with international search report (Art. 21(3)) (84) (71) Applicant: MANNKIND CORPORATION [US/US]; 25134 Rye Canyon Loop, Suite 300, Valencia, CA 91355 (US). (54) Title: DRY POWDER INHALER 13 (57) : A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovas - cular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation.
SG11201806304PA 2016-01-29 2017-01-27 Dry powder inhaler SG11201806304PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662289095P 2016-01-29 2016-01-29
PCT/US2017/015486 WO2017132601A1 (en) 2016-01-29 2017-01-27 Dry powder inhaler

Publications (1)

Publication Number Publication Date
SG11201806304PA true SG11201806304PA (en) 2018-08-30

Family

ID=59386335

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806304PA SG11201806304PA (en) 2016-01-29 2017-01-27 Dry powder inhaler

Country Status (12)

Country Link
US (4) US20170216538A1 (en)
EP (2) EP4079291A1 (en)
JP (3) JP2019504684A (en)
CN (2) CN114904100A (en)
AU (2) AU2017211410B2 (en)
BR (1) BR112018015444B1 (en)
CA (2) CA3012679C (en)
HK (1) HK1258955A1 (en)
IL (1) IL260823B1 (en)
MX (2) MX2018009159A (en)
SG (1) SG11201806304PA (en)
WO (1) WO2017132601A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101306384B1 (en) 2004-08-23 2013-09-09 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
JP5465878B2 (en) 2005-09-14 2014-04-09 マンカインド コーポレイション Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CN104689432B (en) 2008-06-13 2018-07-06 曼金德公司 Diskus and the system for drug conveying
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
JP5479465B2 (en) 2008-06-20 2014-04-23 マンカインド コーポレイション Interactive device and method for profiling inhalation efforts in real time
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
BR112016000937A8 (en) 2013-07-18 2021-06-22 Mannkind Corp dry powder pharmaceutical formulations, method for making a dry powder formulation and use of a dry powder pharmaceutical formulation
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
WO2015200049A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
USD824015S1 (en) * 2016-01-29 2018-07-24 Mannkind Corporation Inhaler
USD824016S1 (en) * 2016-01-29 2018-07-24 Mannkind Corporation Inhaler
USD824510S1 (en) * 2016-01-29 2018-07-31 Mannkind Corporation Inhaler
USD841798S1 (en) * 2016-01-29 2019-02-26 Mannkind Corporation Inhaler
AU2017261317A1 (en) * 2016-05-05 2018-12-13 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
US20180271826A1 (en) * 2017-03-22 2018-09-27 Colorado Can Llc Dry powders of cannabinoids and methods for preparing dry powders
USD834178S1 (en) * 2017-05-19 2018-11-20 Mannkind Corporation Inhaler
WO2018233794A1 (en) * 2017-06-23 2018-12-27 Københavns Universitet Inhaler with acoustic flow monitoring
USD851748S1 (en) * 2017-11-08 2019-06-18 Mannkind Corporation Inhaler
JP2021510723A (en) * 2018-01-26 2021-04-30 ノバルティス アーゲー High-dose delivery of inhaled therapeutics
EP3801552A4 (en) * 2018-06-07 2022-02-23 MannKind Corporation Composition and method for inhalation
CA3133804A1 (en) * 2019-03-22 2020-10-01 Mannkind Corporation Inhalable dry powders
USD898187S1 (en) * 2019-05-21 2020-10-06 Receptor Holdings, Inc. Inhaler device
KR20220064376A (en) * 2019-09-18 2022-05-18 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Compositions of Cannabinoids for Delivery by Inhalation
US20230117531A1 (en) * 2020-03-19 2023-04-20 Tff Pharmaceuticals, Inc. Dried particle inhalation for delivery of cannabis
CA3187628A1 (en) * 2020-06-19 2021-12-23 Cannovex Bv Pulmonary formulation comprising cannabinoids
CN115089825A (en) * 2022-07-06 2022-09-23 苏州易合医药有限公司 Lung drug delivery device
WO2024059819A2 (en) 2022-09-15 2024-03-21 Tff Pharmaceuticals, Inc. Compositions of cannabinoids for delivery by inhalation

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
WO1999027920A2 (en) * 1997-12-03 1999-06-10 Britannia Pharmaceuticals Limited Use of phospholipids for the manufacture of a medicament for the treatment of asthma
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
WO2003094890A1 (en) * 2002-05-07 2003-11-20 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
TWI313181B (en) * 2002-12-13 2009-08-11 Otsuka Pharma Co Ltd Inhalation device for transpulmonary administration
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
EP1703932A1 (en) * 2003-12-15 2006-09-27 Alexza Molecular Delivery Corporation Treatment of breakthrough pain by drug aerosol inhalation
US7452524B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
DE102004006450B4 (en) * 2004-02-05 2012-09-27 Ing. Erich Pfeiffer Gmbh metering
KR20070054644A (en) * 2004-07-26 2007-05-29 액테리온 파마슈티칼 리미티드 Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
MX2007001903A (en) 2004-08-20 2007-08-02 Mannkind Corp Catalysis of diketopiperazine synthesis.
KR101306384B1 (en) * 2004-08-23 2013-09-09 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
US20090170775A1 (en) * 2004-10-08 2009-07-02 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide compositions
EP1874339A1 (en) * 2005-04-21 2008-01-09 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
JP5465878B2 (en) * 2005-09-14 2014-04-09 マンカインド コーポレイション Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CA2631493A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
ES2707548T3 (en) * 2006-05-15 2019-04-04 United Therapeutics Corp Administration of treprostinil using a metered dose inhaler
US20080078382A1 (en) * 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
WO2008049000A2 (en) * 2006-10-18 2008-04-24 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
US8614255B2 (en) * 2007-08-21 2013-12-24 Civitas Therapeutics, Inc. Pulmonary pharmaceutical formulations
AU2008316636B2 (en) * 2007-10-24 2014-02-06 Mannkind Corporation Delivery of active agents
WO2009152160A1 (en) * 2008-06-10 2009-12-17 Gilead Sciences, Inc. Inhaled carbaprostacyclin and prostacyclin prodrugs for the treatment of pulmonary arterial hypertension
CN104689432B (en) * 2008-06-13 2018-07-06 曼金德公司 Diskus and the system for drug conveying
JP2012503668A (en) * 2008-09-25 2012-02-09 アラダイム コーポレーション Pulmonary delivery of treprostinil deep into the lung
CA2992927A1 (en) 2009-03-18 2010-09-23 Mannkind Corporation Inhaler adaptor for a laser diffraction apparatus and method for measuring particle size distribution
EP2440184B1 (en) * 2009-06-12 2023-04-05 MannKind Corporation Diketopiperazine microparticles with defined specific surface areas
MY172858A (en) * 2009-06-12 2019-12-12 Mannkind Corp Diketopiperazine microparticles with defined isomer contents
WO2011053963A1 (en) * 2009-11-02 2011-05-05 Mannkind Corporation Reactor for producing pharmaceutical particles in a precipitation process
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
RU2571331C1 (en) * 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
DK3470057T3 (en) * 2010-09-29 2021-11-22 Pulmatrix Operating Co Inc CATIONIC DRY POWDER INCLUDING MAGNESIUM SALT
MX354828B (en) * 2010-09-29 2018-03-22 Pulmatrix Operating Co Inc Monovalent metal cation dry powders for inhalation.
EP2526926A1 (en) * 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biocompatible nanopolymer particles with active agents for pulmonary application
CN107596518B (en) * 2012-02-29 2021-04-23 普马特里克斯营业公司 Inhalable dry powder
US20150231067A1 (en) * 2012-08-29 2015-08-20 Mannkind Corporation Method and composition for treating hyperglycemia
US20150313868A1 (en) * 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
EP3587404B1 (en) * 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
ITMI20130572A1 (en) * 2013-04-10 2014-10-11 Eratech Srl COMPOSITION INCLUDING AT LEAST TWO DRIED POWDERS OBTAINED FOR DRY SPRAYS TO INCREASE THE STABILITY OF THE FORMULATION
BR112016000937A8 (en) * 2013-07-18 2021-06-22 Mannkind Corp dry powder pharmaceutical formulations, method for making a dry powder formulation and use of a dry powder pharmaceutical formulation
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
WO2015138423A1 (en) * 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
JO3624B1 (en) * 2014-05-08 2020-08-27 Lilly Co Eli ): rapid-acting insulin compositions
WO2017127641A1 (en) * 2016-01-20 2017-07-27 Flurry Powders Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
WO2019195711A1 (en) * 2018-04-06 2019-10-10 Lupin Inc. Medicament dispenser

Also Published As

Publication number Publication date
AU2017211410A1 (en) 2018-08-09
MX2018009159A (en) 2019-06-13
CA3012679C (en) 2023-12-12
AU2017211410B2 (en) 2022-10-13
EP3407870A4 (en) 2019-07-31
BR112018015444B1 (en) 2023-12-19
IL260823B1 (en) 2024-04-01
MX2023001592A (en) 2023-03-15
CN108778249A (en) 2018-11-09
IL260823A (en) 2024-04-01
US20230098083A1 (en) 2023-03-30
BR112018015444A2 (en) 2018-12-18
US20170216538A1 (en) 2017-08-03
HK1258955A1 (en) 2019-11-22
CA3012679A1 (en) 2017-08-03
WO2017132601A1 (en) 2017-08-03
JP2023154079A (en) 2023-10-18
JP2019504684A (en) 2019-02-21
US20200046917A1 (en) 2020-02-13
CN114904100A (en) 2022-08-16
US20210146071A1 (en) 2021-05-20
JP2022160697A (en) 2022-10-19
EP3407870B1 (en) 2022-06-29
EP4079291A1 (en) 2022-10-26
CA3199504A1 (en) 2017-08-03
EP3407870A1 (en) 2018-12-05
CN108778249B (en) 2022-05-27
AU2022224822A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
SG11201806304PA (en) Dry powder inhaler
SG11201903946SA (en) Devices and methods for slurry generation
SG11201809605PA (en) Compositions for and method of treating acid-base disorders
SG11201811549UA (en) Boronic acid derivatives and therapeutic uses thereof
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201407961WA (en) Risperidone or paliperidone implant formulation
SG11201408261UA (en) Syringe
SG11201407397WA (en) Formulations and methods for vaginal delivery of antiprogestins
SG11201408174UA (en) Antibody formulation
SG11201407340YA (en) Treatment of myelosuppression
SG11201407349UA (en) Proliposomal testosterone formulations
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201807965YA (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
SG11201406987UA (en) Glucokinase activator compositions for the treatment of diabetes
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201805072PA (en) Nicotine powder delivery system
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201807250PA (en) Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
SG11201903431SA (en) Sstr-targeted conjugates and particles and formulations thereof
SG11201407110QA (en) Novel dosage form and formulation of abediterol
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201803915UA (en) Echinomycin formulation, method of making and method of use thereof
SG11201807977XA (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor